The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Open accessAbstract
We report on chloroquine, a 4-amino-quinoline, as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro. Chloroquine is a clinically approved drug effective against malaria. We tested chloroquine phosphate for its antiviral potential against SARS-CoV-induced cytopathicity in Vero E6 cell culture. Results indicate that the IC50 of chloroquine for antiviral activity (8.8 ± 1.2 μM) was significantly lower than its cytostatic activity; CC50 (261.3 ± 14.5 μM), yielding a selectivity index of 30. The IC50 of chloroquine for inhibition of SARS-CoV in vitro approximates the plasma concentrations of chloroquine reached during treatment of acute malaria. Addition of chloroquine to infected cultures could be delayed for up to 5 h postinfection, without an important drop in antiviral activity. Chloroquine, an old antimalarial drug, may be considered for immediate use in the prevention and treatment of SARS-CoV infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, J., Lai, S., Poon, L., Guan, Y., Yam, L., Lim, W., Nicholls, J., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,915
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M.-H., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,474
The Genome Sequence of the SARS-Associated Coronavirus
Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A., Butterfield, Y. S. N., Khattra, J., Asano, J. K., Barber, S. A., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,026
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., & De Clercq, E. (1988) · Journal of Virological Methods · doi:10.1016/0166-0934(88)90134-6 · Cited by 1,642
Effects of chloroquine on viral infections: an old drug against today's diseases
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., & Cauda, R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00806-5 · Cited by 1,268
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13615-x · Cited by 1,158
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
Kuiken, T., Fouchier, R. A., Schutten, M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D., Laman, J. D., de Jong, T., van Doornum, G., Lim, W., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13967-0 · Cited by 1,020
Chan, K., Lai, S. T., Chu, C., Tsui, E. L. H., Tam, C. Y., Wong, M. M.-L., Tse, M. W., Que, T. L., Peiris, M. J. S., Sung, J. J. �., et al. (2003) · PubMed · Cited by 423
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
Yamamoto, N., Yang, R., Yoshinaka, Y., Amari, S., Nakano, T., Cinatl, J., Rabenau, H., Doerr, H. W., Hunsmann, G., Otaka, A., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.083 · Cited by 306
Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide
Wu, C.-J., Jan, J.-T., Chen, C.-M., Hsieh, H.-P., Hwang, D.-R., Liu, H.-W., Liu, C.-Y., Huang, H.-W., Chen, S.-C., Hong, C.-F., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2693-2696.2004 · Cited by 240
Microculture tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS
Goodwin, C. J., Holt, S. J., Downes, S., & Marshall, N. J. (1995) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)00277-4 · Cited by 236
Fronhoffs, S., Totzke, G., Stier, S., Wernert, N., Rothe, M., Brüning, T., Koch, B., Sachinidis, A., Vetter, H., & Ko, Y. (2002) · Molecular and Cellular Probes · doi:10.1006/mcpr.2002.0405 · Cited by 214
Keyaerts, E., Vijgen, L., Chen, L., Maes, P., Hedenstierna, G., & Van Ranst, M. (2004) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2004.04.012 · Cited by 161
Self-citationInhibition of Human Immunodeficiency Virus Infectivity by Chloroquine
Tsai, W.-P., Nara, P. L., Kung, H., & Oroszlan, S. I. (1990) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1990.6.481 · Cited by 152
Proliferative growth of SARS coronavirus in Vero E6 cells
Ng, M. L., Tan, S., See, E., Ooi, E. E., & Ling, A. E. (2003) · Journal of General Virology · doi:10.1099/vir.0.19505-0 · Cited by 114
The anti-HIV-1 activity of chloroquine
Savarino, A., Gennero, L., Sperber, K. E., & Boelaert, J. R. (2001) · Journal of Clinical Virology · doi:10.1016/s1386-6532(00)00139-6 · Cited by 111
Human Coronavirus HCoV-229E Enters Susceptible Cells via the Endocytic Pathway
Blau, D. M., & Holmes, K. V. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-1325-4_31 · Cited by 74
Role of interferons in the treatment of severe acute respiratory syndrome
Cinatl, J. J., Michaelis, M., Scholz, M., & Doerr, H. W. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.6.827 · Cited by 43
Chloroquine Treatment in Rheumatoid Arthritis
Wollheim, F. A., Hanson, A., & Laurell, C. (1978) · Scandinavian Journal of Rheumatology · doi:10.3109/03009747809095649 · Cited by 39
Antiviral treatment of SARS: can we draw any conclusions?
Zhaori, G. (2003) · PubMed · Cited by 29
Cited by
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., & Yuen, K. Y. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-07 · Cited by 1,192
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Colson, P., Rolain, J.-M., Lagier, J.-C., Brouqui, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105932 · Cited by 937
“Regarding viruses, for reasons probably partly identical involving alkalinisation by chloroquine of the phagolysosome, several studies have shown the effectiveness of this molecule, including against coronaviruses among which is the severe acute respiratory syndrome (SARS)-associated coronavirus [1,12,13] (Table 1).”
Metadata
- Authors
- Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. V.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 323
- Issue
- 1
- Pages
- 264-268
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2150119943
- Cited by
- 649
- References
- 23
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.